Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yasukawa, M.
Right arrow Articles by Fujita, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yasukawa, M.
Right arrow Articles by Fujita, S.
Related Collections
Right arrow Immunobiology
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 92 No. 9 (November 1), 1998: pp. 3355-3361

CD4+ Cytotoxic T-Cell Clones Specific for bcr-abl b3a2 Fusion Peptide Augment Colony Formation by Chronic Myelogenous Leukemia Cells in a b3a2-Specific and HLA-DR-Restricted Manner

Masaki Yasukawa, Hideki Ohminami, Shin Kaneko, Yoshihiro Yakushijin, Yasuharu Nishimura, Koiti Inokuchi, Tsuyoshi Miyakuni, Shinji Nakao, Kenji Kishi, Ichiro Kubonishi, Kazuo Dan, and Shigeru Fujita

From the First Department of Internal Medicine, Ehime University School of Medicine, Ehime; the Division of Immunogenetics, Department of Neuroscience and Immunology, Kumamoto University Graduate School of Medical Sciences, Kumamoto; the Division of Hematology, Third Department of Internal Medicine, Nippon Medical School, Tokyo; the Department of Internal Medicine, Okinawa Prefectural Hospital, Okinawa; the Third Department of Internal Medicine, Kanazawa University School of Medicine, Ishikawa; the First Department of Internal Medicine, Niigata University School of Medicine, Niigata; and the Third Department of Internal Medicine, Kochi Medical School, Kochi, Japan.

Although it is well known that CD8+ cytotoxic T lymphocytes (CTLs) play an important role in the suppression of cancer cell growth, the significance of CD4+ CTLs in resistance to cancer is obscure. In an attempt to elucidate the role of CD4+ CTLs in immunosurveillance of chronic myelogenous leukemia (CML), we examined the immunologic functions of bcr-abl b3a2 fusion peptide-specific CD4+ CTL clones. Seven CD4+ T-cell clones that responded to stimulation with b3a2 peptide, but not with b2a2 peptide or physiological counterparts bcr b3b4 and abl 1A-a2 peptides, were established from two healthy individuals. Restriction elements of these clones were HLA-DRB1*0901. These CD4+ T-cell clones exhibited b3a2 peptide-specific and HLA-DRB1*0901-restricted cytotoxicity and produced interleukin-3 (IL-3), IL-4, IL-10, interferon-gamma , tumor necrosis factor-alpha , and granulocyte-macrophage colony-stimulating factor in response to bcr-abl peptide stimulation, indicating they were Th0 clones. The numbers of HLA-DRB1*0901-positive b3a2, but not those of b2a2-positive or HLA-DRB1*0901-negative CML cell colonies increased when CML cells were cultured with b3a2-specific CD4+ CTL clones. These data suggest that bcr-abl-specific CD4+ CTLs recognize CML cells in an antigen-specific and HLA-DR-restricted manner, and that they do not inhibit, but in fact augment, CML cell growth.

© 1998 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
Y. Guo, H. Niiya, T. Azuma, N. Uchida, Y. Yakushijin, I. Sakai, T. Hato, M. Takahashi, S. Senju, Y. Nishimura, et al.
Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner
Blood, August 15, 2005; 106(4): 1415 - 1418.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa
Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes
Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Cathcart, J. Pinilla-Ibarz, T. Korontsvit, J. Schwartz, V. Zakhaleva, E. B. Papadopoulos, and D. A. Scheinberg
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
Blood, February 1, 2004; 103(3): 1037 - 1042.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Kakimoto, A. Hasegawa, S. Fujita, and M. Yasukawa
Phenotypic and Functional Alterations of Dendritic Cells Induced by Human Herpesvirus 6 Infection
J. Virol., September 11, 2002; 76(20): 10338 - 10345.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-Y. Sun, R. S. Krouse, S. J. Forman, D. Senitzer, I. Sniecinski, S. Chatterjee, and K. K. Wong Jr.
Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro
Cancer Res., June 1, 2002; 62(11): 3175 - 3183.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. E. Clark, I. A. Dodi, S. C. Hill, J. R. Lill, G. Aubert, A. R. Macintyre, J. Rojas, A. Bourdon, P. L. R. Bonner, L. Wang, et al.
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
Blood, November 15, 2001; 98(10): 2887 - 2893.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Kobayashi, J. Lu, and E. Celis
Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen
Cancer Res., October 1, 2001; 61(20): 7577 - 7584.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Yasukawa, H. Ohminami, K. Kojima, T. Hato, A. Hasegawa, T. Takahashi, H. Hirai, and S. Fujita
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes
Blood, September 1, 2001; 98(5): 1498 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. K. Sarkar and J. G. Nuchtern
Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes
Cancer Res., April 1, 2000; 60(7): 1908 - 1913.
[Abstract] [Full Text]


Home page
BloodHome page
M. Yasukawa, H. Ohminami, J. Arai, Y. Kasahara, Y. Ishida, and S. Fujita
Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans
Blood, April 1, 2000; 95(7): 2352 - 2355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, and D. A. Scheinberg
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
Blood, March 1, 2000; 95(5): 1781 - 1787.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Ohminami, M. Yasukawa, and S. Fujita
HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
Blood, January 1, 2000; 95(1): 286 - 293.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. J.A. ten Bosch, J. H. Kessler, A. M. Joosten, A. A. Bres-Vloemans, A. Geluk, B. C. Godthelp, J. van Bergen, C. J.M. Melief, and O. C. Leeksma
A BCR-ABL Oncoprotein p210b2a2 Fusion Region Sequence Is Recognized by HLA-DR2a Restricted Cytotoxic T Lymphocytes and Presented by HLA-DR Matched Cells Transfected With an Iib2a2 Construct
Blood, August 1, 1999; 94(3): 1038 - 1045.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020